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Abstract 
Objectives: The aim of this study was to investigate the effects of citrulline (Cit) supplementation on inflammatory 
markers and liver histopathology in patients with non-alcoholic fatty liver disease (NAFLD). In this clinical trial, fifty 
NAFLD patients were assigned to receive 2 g/day Cit or placebo for 3 months.
Results: At the end of study, serum high sensitive C-reactive protein (hs-CRP) and activity of nuclear factor kappa 
B (NF-κB) were reduced in Cit group significantly more than placebo group (P-value = 0.02 and < 0.01 respectively). 
Serum concentrations of tumor necrosis factor-α (TNF-α) was reduced in Cit group significantly more than placebo 
after adjusting for levels of baseline (P-value < 0.001). Moreover, Cit supplementation decreased serum alanine ami-
notransferase (ALT) and hepatic steatosis significantly (P = 0.04). Anthropometric measurements and hepatic enzymes 
did not change significantly in any group (P ≥ 0.05). In conclusion, our results showed that 12 weeks supplementation 
with 2 g/day Cit improved inflammatory markers in patients with NAFLD. Further studies with longer period of sup-
plementation and different dosages of Cit are needed to be able to conclude.
Trial registration IRCT201703194010N18 on 2017-10-13
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Introduction
Non-alcoholic fatty liver disease (NAFLD) begins from 
simple steatosis, and if it is not treated it may progress 
to non-alcoholic steatohepatitis (NASH), cirrhosis, and 
even hepatocellular [1–3]. Inflammation and lobular bal-
looning result from insistent hepatic injury then they can 
cause nonalcoholic steatohepatitis (NASH) and lastly 
may lead to cirrhosis [1]. NAFLD and NASH are revers-
ible, while cirrhosis exhibit an irreversible stage of the 
disease [4]. The only proven treatment for NAFLD is 
lifestyle modification [2, 5], which can be more effective 
when combined with some dietary supplements [6–10].
Specific amino acids such as Citrulline (Cit) supple-
mentation are suggested as effective strategies in ame-
lioration of hepatic steatosis and insulin resistance (IR) 
in experimental models of NAFLD. They could improve 
hepatic steatosis through their effects on glucose toler-
ance, IR and lipid metabolism [11–14]. Some studies have 
shown potential effects of Cit on reducing inflammatory 
markers such as tumor necrosis factor α (TNF-α) and 
interleukin-6 (IL-6) [12, 15, 16], which can prevent devel-
opment of disease to severe conditions such as NASH 
and cirrhosis [17]. The aim of current study was to inves-
tigate effects of Cit supplementation on liver enzymes, 
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inflammatory indices, hepatic elasticity, and echogenicity 




The study protocol was approved by the National Nutri-
tion and Food Technology Research Institute of Sha-
hid Beheshti University of Medical Science (IR.SBMU.
nnftri.13950106). The trial was registered at Iranian reg-
istry of clinical trials (IRCT201703194010N18).
Study design and participants
The study designed as a prospective randomized, Dou-
ble-Blind, placebo-controlled, clinical trial. Patients with 
NAFLD were recruited from a private Hepatology clinic. 
NAFLD was diagnosed by a gastroenterologist according 
to Fibroscan results. Inclusion criteria included age older 
than 18 year and controlled attenuation parameter (CAP) 
score more than 260 in Fibroscan. Exclusion criteria 
included pregnancy and lactation in women, viral hepa-
titis, intake of alcohol, insulin injections and consuming 
hepatotoxic medications.
After explanation of study protocol, patients who 
agreed to participate in the study were randomly 
assigned to receive four capsules/day of either placebo 
(maltodextrin) or Cit (0.5  g) for 12  weeks. Cit capsules 
were filled by 500  mg l-citrulline Maleate, provided by 
Mardin Company, Tehran, Iran. Capsules containing Cit 
or placebo were identical in shape, size and color. Cap-
sules containing Cit or placebo were placed in boxes, 
and labeled as A or B by a third person so that investi-
gators and patients were blinded on group assignments. 
Both groups have been advised on an energy-balanced 
diet according to Clinical Guidelines on the Identifica-
tion, Evaluation, and Treatment of Overweight and Obe-
sity in Adults from the National Institutes of Health and 
the North American Association [18]. Follow-up assess-
ments have been implemented every 4 weeks after start 
of intervention. Compliance was evaluated through cap-
sule count in each visit.
Clinical and paraclinical assessments
Weight, height, and waist circumferences of all partici-
pants were measured. BMI was calculated using the fol-
lowing formula: BMI = weight (kg)/height2 (m). Serum 
alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) were measured by photometric 
assay (Parsazmoun). Levels of gamma glutamine trans-
ferase (GGT) was measured by enzymatic colorimetric 
assay (Parsazmoun). Concentrations of fasting TNF-α 
(TNF-α; BOSTER, Pleasanton, CA, USA) and high-sen-
sitivity C_reactive protein (hs-CRP) were measured by 
using an enzyme-linked immunosorbent assay (Bionik). 
Nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) p65 was assessed in peripheral blood 
mononuclear cell  (PBMC) nuclear extracts using ELISA 
kits (Cell Signaling) according to the manufacturer’s pro-
tocol. Hepatic steatosis and fibrosis were measured using 
FibroScan, and Ultrasound exam, which weredone at the 
beginning and end of the intervention by a hepatologist 
and a radiologist respectively. Assessment of physical 
activity was done at baseline and end of intervention by 
employing the metabolic equivalent of task (MET) ques-
tionnaire [19].
Dietary assessment
Three 24-h recalls for 2  weekdays and 1  weekend day 
were asked from participants at the beginning and end of 
study. Interviews were done by an expert dietitian. Nutri-
ent intakes were assessed using Nutritionist 4 (First Data-
Bank) [20].
Statistical analysis
Data analyzed using SPSS21 software. Continuous and 
categorical data were presented as mean values with their 
standard deviations and frequency. Analyze of demo-
graphic variable were performed using t test or χ2, as 
appropriate. Normal distribution of data was evaluated 
using the Kolmogorov–Smirnov. Paired t test and student 
t test were used to compare variables within and between 
groups respectively. In order to exclude the effects of 
confounding factors, the analysis of covariance test was 
used. All ANCOVA models were adjusted for the base-
line value of each variable and mean changes in BMI, 
MET and energy.
The sample size was calculated for the Fibroscan con-
trolled attenuation parameter (CAP) score. Determin-
ing sample size for this study was based on detection of 
a 10 unit difference in the mean CAP score with a power 
of 80% (β = 20%), yielding a sample size of 21 for each 
group. Due to the potential loss of samples, 25 patients in 
each group were considered [9].
Results
Fifty patients who met the study inclusion criteria were 
enrolled in this study. The flow chart of study enroll-
ment is shown in Fig. 1. Eighty-three percent of patients 
completed 12 weeks of study protocol. Only three (12%) 
patient in the Cit group and three (12%) patient in the 
placebo group discontinued the study for personal rea-
sons. The demographic, inflammatory and biochemical 
characteristics and liver histological parameters of two 
groups were similar at the baseline, only levels of TNF-α 
was significantly higher in placebo group at baseline.
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There were no significant differences in waist circum-
ference, BMI and weight between and within groups. 
Serum ALT was significantly reduced in Cit group after 
12  weeks intervention period, while serum AST and 
GGT did not change significantly in any group.
NF-κb activity and hs-CRP reduced significantly in the 
Cit group compared with the baseline and the placebo 
group (Table  1). After adjusting for levels of baseline, 
TNF-α was reduced in Cit group significantly more than 
placebo group (P = 0.049).
At the end of the study, results of Fibroscan showed a 
significant reduction of Hepatic steatosis and fibrosis in 
the Cit group; however, this reduction was not signifi-
cantly different between groups (P > 0.05). According to 
Ultrasound exam, hepatic steatosis grade reduced in Cit 
group significantly more than placebo group (Table 2).
Discussion
To our knowledge, this study is the first randomized, 
clinical trial that evaluated the effect of Cit supplementa-
tion on markers of inflammation in patient with NAFLD. 
Results of this study have shown that consumption of 2 g/
day Cit reduced markers of inflammation significantly.
The results of previous experimental studies are con-
sistent with our results. Experimental studies have shown 
that Cit supplementation can reduce gene expression of 
Toll-like receptor 4 (TLR4), which results in inhibition of 
NF-kB activation and TNF-α production [11, 15, 16].
Another suggested mechanism for anti-inflammatory 
effects of Cit is its properties in reduction of oxida-
tive stress. Cai et  al. reported that Cit supplementation 
increased superoxide dismutase (SOD) activities and 
reduced levels of malondialdehyde (MDA) [21]. SOD can 
reduce extracellular signal-regulated protein kinases 1 
and 2 (ERK1/2) signaling activation. ERK1/2 inhibition 
leads to prevention of NF-kB activation and TNF-α pro-
duction [22].
Moreover, Sellmann et al. showed that Cit supplemen-
tation protects animals fed a high fructose diet against 
hepatic lipid peroxidation. Increased lipid peroxidation is 
the main cause of redox sensitive nuclear factor κB activ-





















Fig. 1 Flowchart of study participants’ enrolment
Table 1 Inflammatory biomarkers of patients at baseline and after 3 month
TNF-α tumor necrosis factor α, hs-CRP C_reactive protein, NF-κB nuclear factor kappa B cells
* P values indicate comparison within groups









Cit 5696 ± 2862 3901 ± 2760 < 0.01 − 1794 ± 2025 0.02
Placebo 6323 ± 4812 6143 ± 4851 0.713 − 180.6 ± 1866
TNF-α (pg/ml)
Cit 15.1 ± 4.74 14.6 ± 2.01 0.66 − 0.55 ± 0.07 0.57
Placebo 18.5 ± 2.04 17.4 ± 1.57 0.05 − 1.29 ± 2.37
NF-κb (ng/mg protein)
Cit 2.46 ± 0.72 2.11 ± 0.42 0.02 − 0.30 ± 0.63 < 0.001
Placebo 1.99 ± 1.34 2.64 ± 0.72 0.09 0.64 ± 1.29
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Our results showed reduction in serum ALT, and 
hepatic steatosis in the Cit group; however there was 
no significant difference between two groups. Results 
of two experimental studies have shown that Cit sup-
plementation along with high-fat diet or 60% fructose 
diet can prevent the induction of raising hepatic stea-
tosis in rat [11, 13]. This discrepancy might be due to 
low dosage of our supplements and/or short duration 
of the study.
Previous studies reported that Cit down regulated 
genes expression of Sterol regulatory element-binding 
transcription factor 1 (SREBF1) and carbohydrate-
responsive element-binding protein (CHREBP), fatty 
acid synthesis (Fas) that decreased de novo lipogen-
esis (DNL). Cit reduced gene expression SREBF1 by 
affecting on mammalian target of rapamycin (mTOR) 
pathway and protein kinase B [13, 25, 26]. All these 
mechanism are involved in development of hepatic 
steatosis. Thus, another possibility for difference in 
our results with these studies is that prevention and 
reduction of hepatic steatosis may require different 
mechanisms. Though Cit supplementation was able 
to prevent fatty liver, its activity in treating fatty liver 
might be not as clear as that in prevention, particularly 
when administered at low dosages and short duration.
The important advantage of this study is that it is the 
first clinical trial that evaluated the effects of Cit on 
inflammation markers in human patients with NAFLD. 
Other strengths of this study is evaluating NF-κB 
activity in PBMC. Furthermore, participants were 
newly diagnosed patients with NAFLD; so, they did 
not receive any treatment before and during the study.
Conclusion
In conclusion, our results showed that 12  weeks sup-
plementation with 2 g/day Cit improved inflammatory 
markers in patients with NAFLD. Further studies with 
longer period of supplementation and different dosages 
of Cit are needed to be able to conclude.
Limitations
One of the limitations of this study was that we did not 
use different dosages of Cit. We could not use higher 
dosages of Cit because we did not find enough evi-
dence for their safety in human. Secondly, we could not 
obtain liver biopsy to estimate hepatic steatosis, and 
fibrosis. Liver biopsy is gold standard for the evalu-
ation of liver fibrosis during of chronic liver diseases. 
However transient elastography  (FibroScan®) used that 
provides quantitative, safely evaluation of NAFLD by 
scaling hepatic steatosis (CAP score) and fibrosis. This 
technique was a reliable, noninvasive way for identifi-
cation of patients with significant hepatic steatosis and 
fibrosis. It is readily, replicability and its score has low 
inter- and intra-observer variability [27, 28]. Thirdly, 
the clinical significance of reduced inflammatory mark-
ers is not clear so additional studies are needed to see if 
these reductions translate to less liver- or cardiovascu-
lar-related endpoints.
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